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LETTERS
Dysbiosis in inflammatory bowel
disease: a role for
bacteriophages?
Intestinal bacteria have been implicated in the
initiation and amplification of inflammatory
bowel disease (IBD). The dysbiosis theory,
reviewed by Tamboli et al (Gut 2004;53:1), is
that an imbalance between putative ‘‘harm-
ful’’ versus ‘‘protective’’ bacterial species may
promote chronic intestinal inflammation.
Although several studies published so far
support this hypothesis, the most vexing
question posed by Tamboli et al remains
‘‘what is the origin of dysbiosis?’’.
Bacteriophages outnumber bacteria by a
factor of 10 in many natural ecosystems,
exert a strong influence on bacterial diversity
and population structure, and are probably
involved in dysbiosis by destabilising bacterial
communities.1 They could be involved indir-
ectly through gene transfer and genome
reorganisation within the bacterial popula-
tion or directly as immunomodulating agents2
or by steric competition for microbe-asso-
ciated molecular patterns on bacterial sur-
faces. However, bacteriophages are a
neglected component of the gut microbiota.
The first viral metagenomic study demon-
strated a wide diversity (1200 genotypes) of
uncultured bacteriophage species.3 The pre-
sent study aimed at measuring the total viral
community associated with the gut mucosa
and comparing viral abundance between
healthy individuals and patients with
Crohn’s disease (CD), and also between the
ulcerated and non-ulcerated mucosa of these
patients.
Fourteen healthy individuals and 19 CD
patients were recruited and gave their
informed consent. Biopsies were obtained
during colonoscopy and, for CD patients,
from non-ulcerated and ulcerated tissues.
Biopsies were disrupted by ultrasonication,
filtered through 0.22 mm membranes and
fixed in glutaraldehyde. For epifluorescence
microscopy, biopsy supernatants were fil-
tered through 0.02 mm membranes. Virus-
like particles (VLPs) were stained with SYBR
Green and counted on triplicate subsamples.
VLPs were detected in every sample, and no
contaminating bacteria were observed
(fig 1A). Strikingly high numbers of VLPs
were observed (fig 1B), with an average of 1.
26109 VLPs/biopsy (4.46107–1.761010).
Transmission electron microscopy demon-
strated that viral particles corresponded to
bacteriophages, with morphotypes consis-
tent with Siphoviridae, Myoviridae and
Podoviridae being the dominant families
(fig 2). Each individual seemed to be
colonised by one dominant phage family.
This result was confirmed by pulse-field gel
electrophoresis of viral genomic DNA (data
not shown). At the mucosal level and with
specific reference to the potential role of
bacteriophages in dysbiosis, CD patients
harboured significantly more VLPs than
healthy individuals (2.96109 vs 1.26108
VLPs/biopsy; Wilcoxon test p = 0.024).
Moreover, decreased amounts of VLPs were
detected in CD ulcerated mucosa, with an
average of 2.16109 VLPs/biopsy compared
with 4.16109 VLPs/biopsy from non-ulcer-
ated mucosa (fig 1). It can be hypothesised
either that more viruses are produced or that
they can survive longer in non-ulcerated
areas. Whether bacterial composition and
abundance differ when comparing non-
ulcerated with ulcerated mucosa is still
controversial although differing bacterioph-
age life cycles (lysis, lysogeny) could be
responsible for some of these discrepancies.
This study shows for the first time a dense
bacteriophage community specifically asso-
ciated with the gut mucosa, reaching 1010/
mm3 of tissue. Significantly more bacterio-
Figure 1 Concentrations of virus-like particles (VLPs) assessed by epifluorescence microscopy on
gut mucosal samples from healthy individuals and Crohn’s disease (CD) patients. (A) SYBR Green I-
stained human mucosal viral concentrate from a healthy individual (concentrate diluted to 5610-4).
(B) Average number of VLPs per biopsy in the different clinical groups. *p = 0.024 Wilcoxon text.
NUM, non-ulcerated mucosa; UM, ulcerated mucosa.
Figure 2 Transmission electron microscopy observation (80 kV,640 000 magnification) of bacteriophage morphotypes from mucosal samples. The
dominant morphotypes are Myoviridae, Podoviridae and Siphoviridae. The grey bar represents 100 nm.
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phages were detected in the mucosa from
CD patients than from healthy individuals.
Tamboli et al discussed risk factors known to
affect the gut microbial composition (host
genetic background, method of birth deliv-
ery, early bacterial colonisation of neonates,
diet and environment) which could be
responsible for dysbiosis. Based on our
results, we postulate that bacteriophages
might also play a key role in the dysregu-
lated immune response of IBD patients to
the mucosal-associated bacterial population.
More detailed studies that relate phage
populations to disturbances in bacterial
populations and the dysregulated host
immune response on larger cohorts would
help in establishing their role in the patho-
genesis of IBD.
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Disseminated tuberculosis in a
Crohn’s disease patient on anti-
TNFa therapy despite
chemoprophylaxis
We read with interest the article by
Rampton et al (Gut 2005;54:1360) concern-
ing the prevention of tuberculosis (TB) in
patients with Crohn’s disease (CD) needing
treatment with anti-tumour necrosis factor
a (TNFa) agents. Opportunistic infections
and particularly TB are of major concern
among patients who are candidates for
treatment with such cytokine inhibitors.
Although in rheumatoid arthritis large pro-
spective studies reveal an increased risk for
TB activation despite appropriate chemo-
prophylaxis,1 2 there is no similar study in
CD patients. We present the case of a CD
patient on therapy with infliximab who
presented with signs and symptoms of
disseminated TB. To the best of our knowl-
edge, this is the first report of disseminated
TB in a patient with CD who had already
received proper chemoprophylaxis prior to
anti-TNFa treatment.
A 42-year-old Greek man was admitted to
our department because of high fever up to
40uC of 10 days duration, weight loss (6 kg
in the last month), dry cough and headache.
His medical history was significant for
inflammatory ileocolonic CD with articular
involvement of 13 years duration. The
patient experienced clinical remission on
therapy with infliximab (5 mg/kg) every
8 weeks and azathioprine (2 mg/kg) for the
last 3 years. Due to a positive PPD (purified
protein derivative) test, he received, with
good compliance, isoniazid (INH) for
2 months prior to commencement of anti-
TNFa therapy and for a total of 6.5 months.
For the last 2 years he was under close
clinical and radiological surveillance (chest
and abdominal CT) because of persistent
lymphadenopathy (axillary, mediastinal and
lower mesenteric) which was attributed to
generalised Bartonellosis after a thorough
work-up that included lymph node and bone
marrow biopsies. He had no signs of infec-
tion on his previous infliximab infusion
1 month prior to this admission.
The physical examination revealed
crackles of the medial and basal areas of
the right lung. Laboratory tests were
significant for leucocytosis (white blood
cells (WBC) = 16.200), elevated erythrocyte
sedimentation rate (ESR; 101 mm/h) and
C- reactive protein (12 mg/dl; normal ,0.
8). CT scanning revealed diffused micro-
nodular lesions in both lungs with a miliary
pattern, and expansion of the pre-existent
lymphadenopathy to the upper mesenter-
ium. MRI of the head revealed a 4 mm
lesion of the left occipitoparietal region
without signs of abscess. Bronchoscopically
obtained lung biopsies and sputum stains
were not diagnostic and thus he underwent
thoracoscopy. Empiric levofloxacin treat-
ment (750 mg/day for 15 days) resulted in
fever remission with a relapse 6 days after
treatment discontinuation. Biopsies taken
from the right lung confirmed the diagnosis
of active tuberculosis (fig 1). Interestingly,
cultures for TB in blood, bronchoalveolar
lavage and sputum were negative. Therapy
with rifampin, INH, pyrazinamide and
ethambutol resulted in an impressive clin-
ical and radiological improvement during
the first month of treatment.
This is the first report of disseminated TB
(chest, abdomen and brain) in a CD patient
on anti-TNFa treatment despite chemopro-
phylaxis with INH. We think that it was a
reactivation of latent TB rather than a new
infection. Looking at the case retrospec-
tively, it seems that the diagnosis of
Bartonellosis (based merely on serological
evidence) was actually missed TB. According
to Rampton’s algorithm and current guide-
lines, 6–9 months of INH chemoprophylaxis
has been proposed for patients with latent
TB with an indication for anti-TNFa treat-
ment. Our case indicates that in CD patients
on anti-TNFa treatment appropriate INH
prophylaxis does not eliminate the risk for
TB activation, and a close follow-up for TB
activation is required. Therapy with quino-
lones, a common empiric treatment in CD
flares, may delay the diagnosis of TB because
of their well-known anti-TB activity.3 Our
case outlines the need of continuous re-
assessment of our practice in preventing
latent TB reactivation in patients on anti-
TNFa agents.
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Authors’ response
Bourikas et al describe a case of disseminated
tuberculosis (TB) in a patient with Crohn’s
disease given 6.5 months isoniazid and
infliximab. Rampton’s paper1 stated that
‘‘although the incidence of infliximab-
related TB may now be falling due to
improved risk assessment, chemoprophy-
laxis, and/or reporting fatigue, complacency
is clearly inappropriate’’ It also summarised
and referred to the full text of the British
Thoracic Society/British Society of
Gastroenterology/British Society of
Rheumatology guidelines2 published in the
same year. Under section 4.6 of the full
guidelines,2 we wrote ‘‘It should be noted
Figure 1 Ziehl–Neelsen stain of a lung tissue
section reveals an acid-fast bacillus (arrow;
magnification 6100).
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